<DOC>
	<DOCNO>NCT01833143</DOCNO>
	<brief_summary>The purpose study test drug Bortezomib see well work . The investigator want find effect , good bad , patient limit smoke history specific mutation associate lung cancer .</brief_summary>
	<brief_title>Bortezomib KRAS-Mutant Non-Small Cell Lung Cancer Never Smokers Those With KRAS G12D</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>Acyclovir</mesh_term>
	<criteria>Pathologic cytologic evidence nonsmall cell lung cancer ( NSCLC ) Documented KRAS mutation History smoking &lt; 100 cigarette ( neversmoker ) OR patient KRAS G12D mutation regardless smoke history Clinical stage IIIB/IV recurrent/medically inoperable NSCLC Age ≥ 18 year Three ( 3 ) week since last chemotherapy , three ( 3 ) week since prior radiation therapy recover treatment Karnofsky performance status ≥ 70 % Adequate hematologic , and/or hepatic function WBC ≥ 3,000/ul absolute neutrophil count ≥ 1,000/ul Hemoglobin ≥ 9.0 g/dl Platelet count ≥ 100,000/ul AST ≤ 2.0 X ULN ( upper limit normal ) Total bilirubin ≤1.5 x ULN Measurable indicator lesion RECIST v1.1 criterion . Voluntary write informed consent performance studyrelated procedure part normal medical care , understand consent may withdraw subject time without prejudice future medical care . Female subject either postmenopausal least 1 year screen visit , surgically sterilize childbearing potential , agree practice 2 effective method contraception time sign informed consent form 30 day last dose bortezomib , agree completely abstain heterosexual intercourse . Male subject must agree 1 following : practice effective barrier contraception entire study treatment period minimum 30 day last dose study drug , completely abstain heterosexual intercourse . Uncontrolled central nervous system metastasis define lesion either a. symptomatic , require escalate dos corticosteroid Significant medical history unstable medical condition uncontrolled diabetes myocardial infarction within 6 month prior enrollment New York Heart Association Class III IV heart failure severe uncontrolled ventricular arrythmias uncontrolled angina ECG evidence acute ischemia active conduction system abnormalities Baseline ≥ grade 2 peripheral neuropathy CTCAE v 4.0 ( Appendix B ) Known hypersensitivity boron mannitol Female patient pregnant/lactating positive serum urine βhCG pregnancy test Serious medical psychiatric illness likely interfere participation clinical study . No active concurrent malignancy , exception insitu malignancy completely resect basal cell carcinoma squamous cell carcinoma skin lowrisk prostate cancer curative therapy Participation clinical trial investigational agent include trial , within 14 day start trial throughout duration trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>KRAS-Mutant</keyword>
	<keyword>Bortezomib</keyword>
	<keyword>KRAS G12D</keyword>
	<keyword>12-222</keyword>
</DOC>